Universal Beteiligungs und Servicegesellschaft mbH Grows Stock Holdings in Innoviva, Inc. $INVA

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH raised its stake in Innoviva by 49.9% in Q4 to 173,119 shares—about 0.23% of the company—valued at roughly $3.46 million.
• Innoviva reported a strong quarter, with EPS of $1.94 vs. $0.34 expected and revenue of $114.61 million versus $102.62 million, delivering a net margin of 65.92% and a return on equity of 37.63%.
• Institutional investors own 99.12% of the stock, and analysts hold a consensus "Moderate Buy" with a $34.80 target (five Buys, one Hold, one Sell) versus the recent ~ $23 share price.

Universal Beteiligungs und Servicegesellschaft mbH raised its position in shares of Innoviva, Inc. (NASDAQ:INVA - Free Report) by 49.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 173,119 shares of the biotechnology company's stock after buying an additional 57,616 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.23% of Innoviva worth $3,457,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Innoviva by 49.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,633 shares of the biotechnology company's stock worth $73,000 after buying an additional 1,197 shares during the period. CWM LLC boosted its position in shares of Innoviva by 24.5% during the fourth quarter. CWM LLC now owns 9,037 shares of the biotechnology company's stock worth $181,000 after buying an additional 1,780 shares during the period. Assetmark Inc. boosted its position in shares of Innoviva by 3.9% during the fourth quarter. Assetmark Inc. now owns 185,319 shares of the biotechnology company's stock worth $3,705,000 after buying an additional 7,018 shares during the period. State of Alaska Department of Revenue boosted its position in shares of Innoviva by 71.1% during the fourth quarter. State of Alaska Department of Revenue now owns 51,549 shares of the biotechnology company's stock worth $1,029,000 after buying an additional 21,424 shares during the period. Finally, Yousif Capital Management LLC boosted its position in shares of Innoviva by 4.0% during the fourth quarter. Yousif Capital Management LLC now owns 19,492 shares of the biotechnology company's stock worth $381,000 after buying an additional 752 shares during the period. 99.12% of the stock is currently owned by hedge funds and other institutional investors.

Innoviva Trading Down 2.7%

NASDAQ:INVA opened at $23.05 on Thursday. Innoviva, Inc. has a 12-month low of $16.52 and a 12-month high of $25.15. The company has a current ratio of 14.64, a quick ratio of 13.85 and a debt-to-equity ratio of 0.22. The firm has a market cap of $1.71 billion, a PE ratio of 7.56 and a beta of 0.40. The stock has a fifty day moving average price of $23.02 and a 200 day moving average price of $21.14.

Innoviva (NASDAQ:INVA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $1.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.34 by $1.60. Innoviva had a return on equity of 37.63% and a net margin of 65.92%.The company had revenue of $114.61 million for the quarter, compared to analysts' expectations of $102.62 million. Sell-side analysts anticipate that Innoviva, Inc. will post 1.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

INVA has been the subject of a number of recent research reports. BTIG Research reiterated a "buy" rating and issued a $35.00 target price on shares of Innoviva in a report on Thursday, February 26th. Weiss Ratings reiterated a "buy (b)" rating on shares of Innoviva in a report on Friday, March 27th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Innoviva presently has an average rating of "Moderate Buy" and a consensus target price of $34.80.

Innoviva Company Profile

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva's portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.